Immunocore Ltd

This is the first human study testing a new immune therapy drug called IMC-P115C for people with advanced cancers that have a specific protein marker called PRAME. The trial will enroll 140 participants to check if the drug is safe and shows early signs of working, both alone and…

This study is testing a new experimental drug called IMC-R117C for people with advanced colorectal, esophageal, gastric, or ovarian cancers. The drug works by directing the body's immune cells to attack cancer cells that have a specific marker called PIWIL1. Researchers will eval…

This study is testing whether a new drug called tebentafusp, given alone or with pembrolizumab, works better than standard care options for people with advanced melanoma that has worsened despite previous treatments. The trial will enroll 540 participants with specific genetic ma…

This Phase 3 trial is testing whether adding a new drug called brenetafusp (IMC-F106C) to the standard immunotherapy nivolumab works better than current treatments for advanced melanoma. It will enroll about 680 people with previously untreated, advanced melanoma who have a speci…